Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 85, Issue 10, 2009, Pages 837-841

  Merlob, Paul ^a,b,c   Birk, Einat ^c,d   Sirota, Lea ^c,d   Linder, Nehama ^a,c   Berant, Michael ^d   Stahl, Bracha ^b   Klinger, Gil ^c,d  

^a RABIN MEDICAL CENTER   (Israel)

^b Beilinson Teratology Information Service   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Congenital heart malformations; Newborn screening; Selective serotonine reuptake inhibitors

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TERATOGENIC AGENT; VENLAFAXINE;

ARTICLE; BICUSPID AORTIC VALVE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; CORONARY SINUS; ECHOCARDIOGRAPHY; FEMALE; FIRST TRIMESTER PREGNANCY; HEART MURMUR; HEART VENTRICLE SEPTUM DEFECT; HUMAN; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN SCREENING; PEDIATRIC CARDIOLOGY; PRENATAL DRUG EXPOSURE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUPERIOR CAVA VEIN; TERATOGENICITY;

CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY; FEMALE; FLUOXETINE; HEART MURMURS; HUMANS; INFANT, NEWBORN; MATERNAL EXPOSURE; PAROXETINE; PREGNANCY; PREVALENCE; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; TERATOGENS;

EID: 70350324239     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20615     Document Type: Article

References (24)

1. Alwan S, Reefhuis J, Rasmussen S, et al. 2005. Maternal use of selective serotonin reuptake inhibitors and risk for birth defects. Birth Defects Res A Clin Mol Teratol 73:291.
2. Alwan S, Reefhuis J, Rasmussen SA, et al. 2007. Use of selective serotonin reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356:2684-2692. (Pubitemid 47001036)
3. Baldwin JA, Davidson EJ, Pritchard AL, Ridings JE. 1989. The reproductive toxicology of paroxetine. Acta Psychiatrica Scand (Suppl) 350:37-39.
4. Bar-Oz B, Einarson T, Einarson A, et al. 2007. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 29:918-926. (Pubitemid 47223423)
5. Berard A, Ramos E, Rey E, et al. 2007. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 80:18-27. (Pubitemid 46303265)
6. Cole JA, Ng EW, Ephross SA, et al. 2006. Paroxetine in the first trimester of pregnancy and the prevalence of congenital malformations [abstract]. Pharmacoepidemiol Drug Safety 15(Suppl):S6.
7. Diav-Citrin O, Shechtman S, Weinbaum D, et al. 2005. Pregnancy outcome after gestation exposure to paroxetine: a prospective controlled cohort study. Presented at the 45th Annual Meeting of the Teratology Society, St. Pete Beach, Florida, June 25-30, 2005; Reprod Toxicol 2005, 20:459.
8. Diav-Citrin O, Schechtman S, Weinbaum DE, et al. 2008. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Brit J Clin Pharmacol 66:695-705.
9. Einarson A, Koren G. 2006. Counseling pregnant women treated with paroxetine. Concern about cardiac malformations. Can Fam Physician 52:593-594.
10. Einarson A, Pistelli A, DeSantis M, et al. 2008. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 165:749-752. (Pubitemid 351810544)
11. Einarson A, Choi J, Einarson TR, Koren G. 2009. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 54:242-246.
12. GlaxoSmithKline. 2005. New safety information regarding paroxetine: findings suggest increased risk over other antidepressants, of congenital malformations, following first trimester exposure to paroxetine. GSK Advisory, Mississauga, Ontario, Canada.
13. Hallberg P, Sjoblom V. 2005. The use of selective serotonin reuptake inhibitors during pregnancy and breast feeding: a review and clinical aspects. J Clin Psychopharmacol 25:59-73. (Pubitemid 40129383)
14. Kallen B, Otterblad Olansson P. 2006. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 21:221-222. (Pubitemid 43294548)
15. Kallen B, Otterblad Olausson P. 2007. Maternal use of selective serotonin reuptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 79:301-308. (Pubitemid 46980405)
16. Levinson-Castiel R, Merlob P, Linder N, et al. 2006. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 160:173-176. (Pubitemid 43213863)
17. Louik C, Lin AE, Werler MM, et al. 2007. First trimester use of selective serotonin reuptake inhibitors and the risk of birth defects. New Engl J Med 356:2675-2683. (Pubitemid 47001035)
18. Malm H, Klaukka T, Neuvonen PJ. 2005. Risk associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 106:1289-1296. (Pubitemid 41668948)
19. O'Brien L, Einarson TR, Sarkar M, et al. 2008. Early gestational exposure to paroxetine and the risk of cardiac malformations: an updated meta-analysis. Birth Defects Res A Clin Mol Teratol 82:371.
20. Reller MD, Strickland MJ, Riehle-Colarusso T, et al. 2008. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr 53:807-813
21. Vial T, Cournot MP, Bernard N, et al. 2006. Paroxetine and congenital malformations: a prospective comparative study [abstract]. Drug Saf 29:970.
22. Wichman CL, Moore KM, Lang TR, et al. 2009. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 84:23-27.
23. Wogelius P, Norgaard M, Muff Munk E, et al. 2005. Maternal use of selective serotonin reuptake inhibitors and risk of adverse pregnancy outcomes. Pharmacoepidemiol Drug Safety 14(Suppl 2):S72.
24. Wogelius P, Norgaard M, Gislum M, et al. 2006. Maternal use of selective serotonin reuptake inhibitors and the risk of congenital malformations. Epidemiology 17:701-704. (Pubitemid 44655607)